Ocugen Inc - Asset Resilience Ratio
Ocugen Inc (OCGN) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ocugen Inc (OCGN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Ocugen Inc's Asset Resilience Ratio has changed over time. See Ocugen Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ocugen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ocugen Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ocugen Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ocugen Inc Industry Peers by Asset Resilience Ratio
Compare Ocugen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Ocugen Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Ocugen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $64.55 Million | -- |
| 2022-12-31 | 12.31% | $13.37 Million | $108.63 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $105.76 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $17.43 Million | -- |
| 2017-12-31 | 8.16% | $900.00K | $11.04 Million | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more